Pfizer (PFE)
Pfizer Free Cash Flow: 2.52B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PFE Free Cash Flow Rankings
| Overall | 98th percentile | 51 of 4353 |
| Sector | 99th percentile | 3 of 501 in Healthcare |
| Industry | 92nd percentile | 2 of 25 in Drug Manufacturers - Major |
PFE Free Cash Flow Range, Past 5 Years
| Minimum | -6.665B | Mar 2010 |
| Maximum | 6.395B | Sep 2010 |
| Average | 3.676B |
About Free Cash Flow
Click "Learn More" below to see how YCharts calculates Free Cash Flow.
Free cash flow is the amount of cash generated by a business that is available for distribution among its security holders. Security holders include debt holders, equity holders, preferred stock holders, and convertible security holders. Specifically, free cash flow is used to pay dividends, make acquisitions, develop new products, invest in new property, plant and equipment, pay interest expenses, and reduce debt.
According to many investors, free cash flow is the best indication of a company's ability to generate cash.
Learn More
You may also be interested in these PFE related companies
PFE News
@SomeGuy900 $DRRX $PFE will meet with the FDA, likely this summer. The good thing about the NDA is that the CRL was a CMC issue, chemistry
about a day ago by SlownSteady
about a day ago by SlownSteady
@rockchalk11 $ARNA Take a look at $DRRX; I bought it a few weeks ago at 72 cents. It's partnered, indirectly, with $PFE on Remoxy (a drug)
about a day ago by SlownSteady
about a day ago by SlownSteady
The Senate passed a bill that reauthorizes fees from drugmakers to fund the FDA. Likely to impact $PFE. http://stks.co/3zSI
about a day ago by ok123jump
about a day ago by ok123jump
@Urbane_Gorilla http://stks.co/3z5t $CYCC $CELG $BMY $REGN $PFE #ASCO12 checklist
about 2 days ago by biotech
about 2 days ago by biotech
Next week should see surge in biotechs ahead of ASCO presentations 1st week in June. $PFE, $MRK, $VVUS
about 2 days ago by EPS_MomentuM
about 2 days ago by EPS_MomentuM
$pfe $Nok and others way down. But, my stock of the month $peix shines with 4% gain. Up after hours too! Clearly a great opportunity.
about 3 days ago by moneyinc365
about 3 days ago by moneyinc365
RT @ianestepan $CLDX if this data was from $BMY,$ONXX,$MDVN,$DNA or $PFE - people would be soooooo excited....
about 3 days ago by N0M0NEY_N0H0NEY
about 3 days ago by N0M0NEY_N0H0NEY
RT @Zraic Only 5 dow stocks are trading above their 20 day and 50 day moving averages $T $DIS $PFE
about 3 days ago by StockTwits
about 3 days ago by StockTwits
Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
May 23, 7:31AM Street Insider
May 23, 7:31AM Street Insider
RT @adamfeuerstein Outlooks for $PFE $ARNA $ONXX -- Weekly #biotech and pharma thoughts from @natesadeghi --> http://stks.co/3uoM
about 5 days ago by AceOfSpades
about 5 days ago by AceOfSpades
Pharma has been a place to hide in pullback, but there are many fewer names that look healthy. $PFE still holding, $LLY looks ready to drop
about 7 days ago by harmongreg
about 7 days ago by harmongreg
Go into Pharma to avoid the bloodbath in the markets. Rotation into safety $PFE $MRK $JNJ http://stks.co/3tbu
about 8 days ago by EPS_MomentuM
about 8 days ago by EPS_MomentuM
Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
May 18, 8:02AM Street Insider
May 18, 8:02AM Street Insider
Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients
May 18, 8:00AM Business Wire
May 18, 8:00AM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PFE | 22.13 | -0.01 | -0.05% | 166.80B |
| PFBC | 12.04 | +0.10 | +0.84% | 158.81M |
| PFA | 14.80 | +0.11 | +0.75% | |
| PETS | 11.88 | +0.17 | +1.45% | 241.64M |
| PER | 19.66 | -0.29 | -1.45% | 774.21M |
| PEGA | 31.71 | -0.06 | -0.19% | 1.199B |
| PDP | 26.51 | -0.09 | -0.34% | |
| PDLI | 6.48 | -0.01 | -0.15% | 906.42M |
| PCLN | 652.88 | -16.09 | -2.41% | 32.51B |
| PCL | 36.71 | -0.31 | -0.84% | 5.925B |
